GS was described many years ago, but the identification of different underlying molecular genetic characteristics (PTCH1 or SUFU germline variants) has changed the way in which this predisposing syndrome is identified and has modified the phenotypic characteristics of the tumor risks historically described. The gene discussed is PTCH1; the disease is neoplasm.